Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Zasocitinib in Psoriatic Arthritis
NCT07286058Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of zasocitinib in psoriatic arthritis (PsA), sponsored by Takeda. Started Mar 2026; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07286058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286058.